Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Rambam Health Care Campus
Patients who were treated for aggressive non-Hodgkin lymphoma with adriamycin containing regimen, CHOP and High dose CHOP with or without rituximab were evaluated post 2 cycles of chemotherapy to rule out disease progression . Currently a retrospective evaluation of PET/CT as a predictive value for progression free survival and overall survival is evaluated
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
aggressive non-Hodgkin lymphoma b cells
age 18-70
bilirubin less then 2
creatinine less then 2
Pet/CT performed post 2 cycles
You may not be if
no PET/CT post 2 cycles performed
bilirubin \>2
creatinine more then 2
HIV positivity
Clareo Health | The Prognostic Value of Interim PET/CT After 2 Cycles of Chemotherapy in Predicting Progression of Non Hodgkins Lymphoma
